SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Raafat S. Alameddine, Ahmad Sharif Yakan, Hadi Skouri, Deborah Mukherji, Sally Temraz, Ali Shamseddine, Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin, Critical Reviews in Oncology/Hematology, 2015,

    CrossRef

  2. 2
    Ole-Petter R. Hamnvik, Toni K. Choueiri, Alexander Turchin, Rana R. McKay, Lipika Goyal, Michael Davis, Marina D. Kaymakcalan, Jonathan S. Williams, Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway, Cancer, 2015, 121, 2
  3. 3
    Giuseppe Bronte, Enrico Bronte, Giuseppina Novo, Gianfranco Pernice, Francesca Lo Vullo, Emmanuela Musso, Fabrizio Bronte, Eliana Gulotta, Sergio Rizzo, Christian Rolfo, Nicola Silvestris, Viviana Bazan, Salvatore Novo, Antonio Russo, Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy, Expert Opinion on Drug Safety, 2015, 14, 2, 253

    CrossRef

  4. 4
    Ying Liu, Yi Liu, Zai-Wen Fan, Jian Li, Guo-Gang Xu, Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib, European Journal of Clinical Pharmacology, 2015, 71, 5, 541

    CrossRef

  5. 5
    Andreas K.A. Gaumann, Friedemann Kiefer, Joachim Alfer, Sven A. Lang, Edward K. Geissler, Georg Breier, Receptor tyrosine kinase inhibitors: Are they real tumor killers?, International Journal of Cancer, 2015, 137, 5
  6. 6
    Rashmi R. Shah, Joel Morganroth, Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit, Drug Safety, 2015,

    CrossRef

  7. 7
    Wei-Xiang Qi, Zan Shen, Li-Na Tang, Yang Yao, Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials, British Journal of Clinical Pharmacology, 2014, 78, 4
  8. 8
    Wei-Xiang Qi, Shen Fu, Qing Zhang, Xiao-Mao Guo, Efficacy and Toxicity of Anti-VEGF Agents in Patients with Castration-Resistant Prostate Cancer: a Meta-analysis of Prospective Clinical Studies, Asian Pacific Journal of Cancer Prevention, 2014, 15, 19, 8177

    CrossRef

  9. 9
    Wei-Xiang Qi, Zan Shen, Li-Na Tang, Yang Yao, Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis, Critical Reviews in Oncology/Hematology, 2014, 92, 2, 71

    CrossRef

  10. 10
    Wei-Xiang Qi, Yuan-Jue Sun, Li-Na Tang, Zan Shen, Yang Yao, Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis, Critical Reviews in Oncology/Hematology, 2014, 89, 3, 394

    CrossRef

  11. 11
    Wei-Xiang Qi, Zan Shen, Li-Na Tang, Yang Yao, Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis, Clinical Drug Investigation, 2014, 34, 4, 231

    CrossRef

  12. 12
    Zexing Wang, Jing Xu, Weiwei Nie, Guichun Huang, Jinhai Tang, Xiaoxiang Guan, Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis, European Journal of Clinical Pharmacology, 2014, 70, 2, 225

    CrossRef

  13. 13
    Tomohiro Funakoshi, Asma Latif, Matthew D. Galsky, Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials, Cancer Treatment Reviews, 2014, 40, 5, 636

    CrossRef

  14. 14
    Wei-Xiang Qi, Li-Na Tang, Zan Shen, Yang Yao, Treatment-related mortality with aflibercept in cancer patients: a meta-analysis, European Journal of Clinical Pharmacology, 2014, 70, 4, 461

    CrossRef

  15. 15
    Antonella De Luca, Amelia D’Alessio, Monica Rosaria Maiello, Marianna Gallo, Simona Bevilacqua, Daniela Frezzetti, Alessandro Morabito, Francesco Perrone, Nicola Normanno, Vandetanib as a potential treatment for breast cancer, Expert Opinion on Investigational Drugs, 2014, 23, 9, 1295

    CrossRef

  16. 16
    Spyridon Karras, Panagiotis Anagnostis, Gerasimos E Krassas, Vandetanib for the treatment of thyroid cancer: an update, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 3, 469

    CrossRef

  17. 17
    Wei-Xiang Qi, Ai-Na He, Zan Shen, Yang Yao, Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis, British Journal of Clinical Pharmacology, 2013, 76, 3
  18. 18
    Devron R. Shah, Rashmi R. Shah, Joel Morganroth, Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy, Drug Safety, 2013, 36, 6, 413

    CrossRef

  19. 19
    Hari A Deshpande, Tobias Carling, Nabeela Khan, Elizabeth Holt, Vandetanib for aggressive and symptomatic medullary thyroid cancer, Clinical Practice, 2013, 10, 3, 275

    CrossRef

  20. 20
    Enrique Grande, Michael C. Kreissl, Sebastiano Filetti, Kate Newbold, Walter Reinisch, Caroline Robert, Martin Schlumberger, Lærke K. Tolstrup, Jose L. Zamorano, Jaume Capdevila, Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies, Advances in Therapy, 2013, 30, 11, 945

    CrossRef